참고문헌
- Steinman RM, Witmer-Pack M, Inaba K: Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv Exp Med Biol 329;1-9, 1998
- von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL: Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 99;3319-3325, 2002 https://doi.org/10.1182/blood.V99.9.3319
- Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190;1669-1678, 1999 https://doi.org/10.1084/jem.190.11.1669
- Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109;409-417, 2002 https://doi.org/10.1172/JCI0214364
- Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, Dummer R, Nestle FO: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102;2338-2344, 2003 https://doi.org/10.1182/blood-2002-08-2455
- Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 6;332-336, 2000 https://doi.org/10.1038/73193
- Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM: CD40- activated human B cells: an alternative source of highly efficient antigen-presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100;2757-2765, 1997 https://doi.org/10.1172/JCI119822
- Kondo E, Topp MS, Kiem HP, Obata Y, Morishima Y, Kuzushima K, Tanimoto K, Harada M, Takahashi T, Akatsuka Y: Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 169;2164-2171, 2002 https://doi.org/10.4049/jimmunol.169.4.2164
- Grewal IS, Flavell RA: CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16;111-135, 1998 https://doi.org/10.1146/annurev.immunol.16.1.111
- Ivanov R, Aarts T, Hagenbeek A, Hol S, Ebeling S: B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. Cytotherapy 7;62-73, 2005 https://doi.org/10.1080/14653240510018055
- Yoon SH, Cho HI, Kim TG: Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro. Exp Mol Med 37;567-574, 2005 https://doi.org/10.1038/emm.2005.70
- Coughlin CM, Vance BA, Grupp SA, Vonderheide RH: RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103;2046-2054, 2004 https://doi.org/10.1182/blood-2003-07-2379
- Okamura T, Uluhan S, Rooney CM: Antigen-presenting ca pabilities of retrovirus-transduced T cell blasts. Blood 102;285a, 2003
- Liu YN, Fuad S, Gehrz RC: Epstein-Barr virus-transformed lymphoblastoid cell lines as antigen-presenting cells and 'augmenting' cells for human CMV-specific Th clones. Cell Immunol 108;64-75, 1987 https://doi.org/10.1016/0008-8749(87)90193-6
- Ascher NL: Issues in xenotransplantation. Liver Transpl Surg 1;320-321, 1995 https://doi.org/10.1002/lt.500010508
- Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 20;143-148, 2002 https://doi.org/10.1038/nbt0102-4
- Dessureault S, Alsarraj M, McCarthy S, Hunter T, Noyes D, Lee D, Harkins J, Seigne J, Jennings R, Antonia SJ: A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 125;173-181, 2005 https://doi.org/10.1016/j.jss.2004.11.036
- Rainaldi G, Calcabrini A, Santini MT: Positively charged polymer polylysine-induced cell adhesion molecule redistribution in K562 cells. J Mater Sci Mater Med 9;755-760, 1998 https://doi.org/10.1023/A:1008915305681
- Schultze JL, Grabbe S, von Bergwelt-Baildon MS: DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol 25;659-664, 2004 https://doi.org/10.1016/j.it.2004.09.016